Animal virology

Global Avian Influenza Clinical Trial Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 30, 2021
Infectious diseases, Health, Clinical trials, Health sciences, Health, Clinical research, Pharmaceutical industry, Drug discovery, Agricultural health and safety, Animal virology, Avian influenza, Clinical trial, Influenza, Influenza pandemic, Influenza research

The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Avian Influenza Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Avian Influenza Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Avian Influenza market.
  • It covers emerging therapies for Avian Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Avian Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Scientific Study at Penn State College of Medicine Confirms ColFlex Oral Spray by INNOTECH NUTRITION Inactivates Human Coronavirus 229E

Retrieved on: 
Wednesday, March 24, 2021
Animal virology, Coronavirus, Human coronavirus 229E, Infection, Medical specialties

The outcome of the study showed very promising results with their "COLFLEX" Oral Spray product.

Key Points: 
  • The outcome of the study showed very promising results with their "COLFLEX" Oral Spray product.
  • Both variations of Innotech Nutrition COLFLEX" Oral Sprays inactivated 99-99.9% of infectious Human Coronavirus 229E (HCoV229E), after a two-minute contact time.
  • The oral spray products were also over 90% effective at inactivating the virus after a 60 second contact time.
  • Innotech Nutritions COLFLEX Oral Spray is a natural health product licensed by Health Canada under NPN 80071606 and has been on the market since 2012.

Sunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment

Retrieved on: 
Tuesday, March 23, 2021
Animal virology, Coronavirus

The proceeds will be used for the ongoing development of the Companys Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Companys flagship anticancer compound targeted for pancreatic cancer.

Key Points: 
  • The proceeds will be used for the ongoing development of the Companys Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Companys flagship anticancer compound targeted for pancreatic cancer.
  • On February 1, 2021, Sunshine Biopharma initiated a transgenic mice study for two Anti-Coronavirus compounds in collaboration with the University of Georgia.
  • On May 22, 2020, Sunshine Biopharma filed a patent application for several molecules which were designed to inhibit the Coronavirus PLpro protease, thus shutting down the ability of the virus to multiply.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.

UVDI V-MAX™ UV-C Technology Proven to Eliminate 99.99% of Airborne SARS-CoV-2 in Moving Airstream HVAC Testing

Retrieved on: 
Thursday, March 11, 2021
Building Systems, Commercial Building & Real Estate, Construction & Property, Manufacturing, Technology, General Health, Infectious diseases, Environment, Other Technology, Other Manufacturing, Science, Other Science, Health, Architecture, Research, Sarbecovirus, Zoonoses, Animal diseases, Medical specialties, Ultraviolet radiation, Animal virology, Bat virome, ASHRAE, Coronavirus disease, Ultraviolet, Coronavirus, Coronavir

UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.

Key Points: 
  • UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.
  • (Photo: Business Wire)
    In the independent testing, UVDI V-MAX UV-C air disinfection technology eliminated 99.99% of SARS-CoV-2 in a single pass at an airflow rate of 500 feet per minute.
  • To confirm effectiveness against airborne SARS-CoV-2 in a moving airstream, Innovative Bioanalysis used a HVAC duct test based on a modified ISO 15714 and ASHRAE 185.1 standard.
  • This novel testing underlines UVDIs UV-C technologys effectiveness against airborne SARS-CoV-2, stated Dr. Ashish Mathur, Ph.D., UVDI Vice President of Innovation and Technology.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection Against SARS-COV, its Variants of Concern and Related Coronaviruses

Retrieved on: 
Tuesday, March 9, 2021
Health sciences, Health, Medical specialties, Zoonoses, Medical research, Antibodies, Animal virology, Virology, Antiviral drug, Neutralizing antibody, Coronavirus disease, Coronavirus

Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.

Key Points: 
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "Covid-19 vaccines will unquestionably be a cornerstone of controlling the pandemic, yet a significant population segment will also need treatments.
  • Hence, passive antibody immunotherapy with potent and broadly neutralizing molecules like our XVR011, to prevent or suppress viral replication in the lower airways, should find an important place in rescuing Covid-19 patients."
  • Exevir's lead asset XVR011 is a single domain-based anti- Covid-19 antibody (VHH-Fc) optimized for stability, safety, broad neutralizing capability and excellent manufacturability.
  • ExeVir Bio is harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses.

Oragenics to Participate in Two Investment Conferences During March

Retrieved on: 
Monday, March 8, 2021
Infectious diseases, Pharmaceutical, Health, Medical specialties, Health sciences, Health, Animal virology, Coronavirus, Lantibiotics, Vaccine

Institutional and other investors interested in scheduling a one-on-one meeting with Oragenics during any of these conferences should contact their sales representative at the sponsoring investment bank.

Key Points: 
  • Institutional and other investors interested in scheduling a one-on-one meeting with Oragenics during any of these conferences should contact their sales representative at the sponsoring investment bank.
  • Oragenics, Inc. is focused on the creation of the Terra CoV-2 development of effective treatments for novel antibiotics against infectious disease.
  • The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.

African swine fever: devising an ‘exit strategy’ for affected countries

Retrieved on: 
Thursday, March 4, 2021
Animal virology, African swine fever virus, Influenza A virus subtype H1N1, Classical swine fever

EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.

Key Points: 
  • EFSA has devised surveillance strategies that will help countries affected by African swine fever (ASF) to determine when the virus has stopped circulating among their wild boar populations.
  • The scientific opinion recommends an exit strategy comprising two phases: a period of routine surveillance of wild boar (the screening phase) followed by a shorter period of intense surveillance (the confirmation phase).
  • Modelling demonstrated that:

    The opinion gives practical examples of how to apply the exit strategy to both large and small affected areas.

  • It also makes recommendations on the minimum monitoring periods needed to make the strategy effective.

Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021
Animal virology, Coronavirus, Health sciences, Health, Medical specialties

A webcast of the virtual presentation will be available starting at 7:00 am (EST) on March 9, 2021, and can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Webcast .

Key Points: 
  • A webcast of the virtual presentation will be available starting at 7:00 am (EST) on March 9, 2021, and can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Webcast .
  • An archived replay of the webcast will be available on the Companys website after the conference.
  • The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.
  • Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).

Avian influenza: 25 EU/EEA countries affected, latest report shows

Retrieved on: 
Saturday, February 27, 2021
Animal virology, Veterinary medicine, Health sciences, Health, Agricultural health and safety, Avian influenza, Influenza A virus subtype H5N8, Influenza, Influenza A virus subtype H7N7, Influenza A virus subtype H5N1

Around 1,000 detections of highly pathogenic avian influenza (HPAI) were reported in 25 EU/EEA countries and the UK between 8 December 2020 and 23 February 2021, according to the latest overview of HPAI in Europe.

Key Points: 
  • Around 1,000 detections of highly pathogenic avian influenza (HPAI) were reported in 25 EU/EEA countries and the UK between 8 December 2020 and 23 February 2021, according to the latest overview of HPAI in Europe.
  • The majority of the 1,022 detections 592 were reported in domestic poultry, with wild and captive birds making up the rest.
  • Seven human cases of A(H5N8) HPAI virus have been reported from Russia, all of them poultry workers with mild or no symptoms.
  • The risk of infection related to avian influenza A(H5N8) virus remains very low for the general population in the EU/EEA and low for occupationally exposed people.